Home » Press Release » 2015 » February 17, 2015

February 17, 2015

Alethia Biotherapeutics Submits a Clinical Trial Application (CTA) for a Phase I Study with AB-16B5, an Inhibitor of EMT in Patients with Advanced Cancers

Alethia PR 150217_EN